Secondary hyperparathyroidism in chronic dialysis patients: Results of the Italian FARO survey on treatment and mortality

Blood Purification

Volumn 32, Issue 2, 2011, Pages 124-132

  Brancaccio, Diego ^a   Cozzolino, Mario ^a   Cannella, Giuseppe ^b   Messa, Piergiorgio ^c   Bonomini, Mario ^d   Cancarini, Giovanni ^e   Caruso, Maria Rosa ^f   Cascone, Carmelo ^g   Costanzo, Anna Maria ^h   Di Luzio Paparatti, Umberto ^h   Mazzaferro, Sandro ⁱ  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c Policlinic Hospital   (Italy)

^d SS Annunziata Hospital   (Italy)

^e SPEDALI CIVILI   (Italy)

^f OSPEDALI RIUNITI   (Italy)

^g S Maria dei Battuti Hospital   (Italy)

^h ABBOTT DIAGNOSTICS   (Italy)

ⁱ SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Calcitriol; Cinacalcet; Dialysis; Paricalcitol; Secondary hyperparathyroidism

Indexed keywords

CALCITRIOL; CALCIUM; CINACALCET; PARATHYROID HORMONE; PARICALCITOL; PHOSPHORUS;

ADULT; AGED; CALCIUM BLOOD LEVEL; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; DEMOGRAPHY; FEMALE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; ITALY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORTALITY; OUTCOME ASSESSMENT; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; PROBABILITY; PROSPECTIVE STUDY; REVIEW; SECONDARY HYPERPARATHYROIDISM;

AGED; CALCITRIOL; CARDIOVASCULAR DISEASES; ERGOCALCIFEROLS; FEMALE; HUMANS; HYPERPARATHYROIDISM, SECONDARY; ITALY; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; NAPHTHALENES; ODDS RATIO; PROSPECTIVE STUDIES; RENAL DIALYSIS; RISK FACTORS; SURVIVAL RATE; VITAMINS;

EID: 79957538341     PISSN: 02535068     EISSN: 14219735     Source Type: Journal    
DOI: 10.1159/000325454     Document Type: Review

References (28)

1. Tentori F: Focus in vitamin D therapy in chronic kidney disease. J Nephrol 2007; 20: 511-514.
2. Martin KJ, Gonzales EA: Metabolic bone disease in chronic kidney disease. J Am Soc Nephrol 2007; 18: 875-885. (Pubitemid 46434504)
3. Cozzolino M, Gallieni M, Brancaccio D, et al: Vitamin D retains an important role in the pathogenesis and management of secondary hyperparathyroidism in chronic renal failure. J Nephrol 2006; 19: 566-577. (Pubitemid 46420075)
4. Dusso AS, Brown AJ, Slatopolsky E: Vitamin D. Am J Physiol Renal Physiol 2005; 289:F8-F28. (Pubitemid 40863568)
5. Salusky IB, Goodman WG: Cardiovascular calcification in end-stage renal disease. Nephrol Dial Transplant 2002; 17: 336-339. (Pubitemid 34157164)
6. Wolisi GO, Moe SM: The role of vitamin D in vascular calcification in chronic kidney disease. Semin Dial 2005; 18: 307-314. (Pubitemid 41159582)
7. Brown AJ, Slatopolsky E: Drug insight: Vitamin D analogs in the treatment of second -ary hyperparathyroidism in patients with chronic kidney disease. Nat Clin Pract Endocrinol Metab 2007; 3: 134-144. (Pubitemid 46146966)
8. Brancaccio D, Bommer J, Coyne D: Vitamin D receptor activator selectivity in the treatment of secondary hyperparathyroidism. Understanding the differences among therapies. Drugs 2007; 67: 1981-1998. (Pubitemid 47524561)
9. Cozzolino M, Galassi A, Gallieni M, Brancaccio D: Pathogenesis and treatment of secondary hyperparathyroidism in dialysis patients: The role of paricalcitol. Curr Vasc Pharmacol 2008; 6: 148-153.
10. Khan S: Vitamin D deficiency and secondary hyperparathyroidism among patients with chronic kidney disease. Am J Med Sci 2007; 333: 201-207. (Pubitemid 46624808)
11. Capuano A, Serio V, Pota A, et al: Beneficial effects of better control of secondary hyperparathyroidism with paricalcitol in chronic dialysis patients. J Nephrol 2009; 22: 59-68.
12. Kalantar-Zadeh K, Kuwae N, Regidor DL, et al: Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int 2006; 70: 771-780. (Pubitemid 44215354)
13. Teng M, Wolf M, Ofsthun MN, et al: Activated injectable vitamin D and hemodialysis survival: A historical cohort study. J Am Soc Nephrol 2005; 16: 1115-1125. (Pubitemid 41710323)
14. Tentori F, Hunt WC, Stidley CA, et al: Mortality risk among hemodialysis patients receiving different vitamin D analogs. Kidney Int 2006; 70: 1858-1865. (Pubitemid 44684819)
15. Naves-Diaz M, Alvarez-Hernandez D, Passlick-Deetjen J, et al: Oral active vitamin D is associated with improved survival in hemodialysis patients. Kidney Int 2008; 74: 1070-1078.
16. Wolf M, Thadani R: Vitamin D in patients with renal failure: A summary of observational mortality studies and steps moving forward. J Steroid Biochem Mol Biol 2007; 103: 487-490. (Pubitemid 46401279)
17. Brancaccio D, Cozzolino M, Galassi A, et al: Management of secondary hyperparathyroidism in uremic patients: The role of the new vitamin D analogs. J Nephrol 2007; 20: 3-9.
18. Levin A, Bakris GL, Molitch M, et al: Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: Results of the study to evaluate early kidney disease. Kidney Int 2007; 71: 31-38. (Pubitemid 44967731)
19. Wolf M, Shah A, Gutierrez O, et al: Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int 2007; 72: 1004-1013. (Pubitemid 47530570)
20. Wolf M, Betancourt J, Chang Y, et al: Impact of vitamin D and race on survival among hemodialysis patients. J Am Soc Nephrol 2008; 19: 1379-1388.
21. Kovesdy CP, Ahmadzadeh S, Anderson JE, Kalantar-Zadeh K: Association of activated vitamin D treatment and mortality in chronic kidney disease. Arch Intern Med 2008; 168: 397-403. (Pubitemid 351350586)
22. Shoben AB, Rudser KD, de Boer ICH, et al: Association of oral calcitriol with improved survival in nondialyzed CKD. J Am Soc Nephrol 2008; 19: 1613-1619.
23. Teng M, Wolf M, Lowrie E, et al: Survival of patients undergoing hemodialisys with paricalcitol or calcitriol therapy. N Engl J Med 2003; 349: 446-456. (Pubitemid 36910023)
24. Tentori F, Albert JM, Young EW, et al: The survival advantage for haemodialysis patients taking vitamin D is questioned: Findings from the Dialysis Outcomes and Practice Patterns Study. Nephrol Dial Transplant 2009; 24: 963-972.
25. Tentori F, Blayney MJ, Albert JM, et al: Mortality risk for dialysis patients with different levels of calcium, phosphorus, and PTH: The Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2008; 52: 519-530.
26. Cunningham J, Danese M, Olson K, Klassen P, Chertow GM: Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture and health-related quality of life in secondary hyperparathyroidism. Kidney Int 2005; 68: 1793-1800. (Pubitemid 43169924)
27. Block GA, Zaun D, Smits G, et al: Cinacalcet hydrochloride treatment significantly improves all-cause and cardiovascular survival in a large cohort of hemodialysis patients. Kidney Int 2010; 78: 578-589.
28. National Kidney Foundation: K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease. Am J Kidney Dis 2003; 42:S1-S202.